Ela fi branor , an Agonist of the Peroxisome Proliferator L Activated Receptor L a and L d , Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening

Université Pierre et Marie Curie, Hôpital Pitié Salpêtrière, Paris, France; Institute of Cardiometabolism and Nutrition, INSERM, UMRS938, Paris, France; Department ofMedicine, Gastroenterology and Hepatology Service, Brooke ArmyMedical Center, Fort Sam Houston, Texas; Department of Gastroenterology and Hepatology, Antwerp University Hospital, University of Antwerp, Antwerp, Belgium; Department of Pathology, Hôpital Beaujon, University Paris-Denis Diderot, Paris, France; Department of Psychiatry, the University of Melbourne, Melbourne, Australia; Faculty of Economics, University of Louvain UCL, Belgique, Belgium; Université Pierre et Marie Curie, Hôpital Saint-Antoine, Paris, France; Unit for the Clinical Management of Digestive Diseases and CIBERehd, Hospital Universitario de Valme, Sevilla; Hepatology Department, University Hospital and LUNAM University, Angers, France; Duke University, Durham, North Carolina; Gastroenterology and Hepatology Division, University of Virginia, Charlottesville, Virginia; Department of Gastroenterology and Hepatology, Radboud University Medical Center, Nijmegen, The Netherlands; Institute of Cellular Medicine, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK; Genfit SA, Loos, France; University of Lille, INSERMUMR1011, Institut Pasteur de Lille, European Genomic Institute for Diabetes, Lille, France; and Virginia Commonwealth University, Richmond, Virginia

[1]  P. Rosenthal,et al.  Effect of Vitamin E or Metformin for Treatment of Nonalcoholic Fatty Liver Disease in Children and Adolescents , 2017 .

[2]  Rachel M. Brown,et al.  Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study , 2016, The Lancet.

[3]  D. Kleiner,et al.  Liver histology and clinical trials for nonalcoholic steatohepatitis-perspectives from 2 pathologists. , 2015, Gastroenterology.

[4]  E. Bjornsson,et al.  Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease. , 2015, Gastroenterology.

[5]  E. van Marck,et al.  PPARα gene expression correlates with severity and histological treatment response in patients with non-alcoholic steatohepatitis. , 2015, Journal of hepatology.

[6]  Mats Fredrikson,et al.  Fibrosis stage is the strongest predictor for disease‐specific mortality in NAFLD after up to 33 years of follow‐up , 2015, Hepatology.

[7]  S. Friedman,et al.  Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: Findings and recommendations from an American Association for the Study of Liver Diseases–U.S. Food and Drug Administration Joint Workshop , 2015, Hepatology.

[8]  B. Neuschwander‐Tetri,et al.  Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial , 2015, The Lancet.

[9]  Philippe Lefebvre,et al.  Molecular mechanism of PPARα action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease. , 2015, Journal of hepatology.

[10]  H. Yki-Järvinen.  Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome. , 2014, The lancet. Diabetes & endocrinology.

[11]  D. Hum,et al.  Hepatoprotective effects of the dual peroxisome proliferator‐activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis , 2013, Hepatology.

[12]  M. Laville,et al.  Dual Peroxisome Proliferator–Activated Receptor α/δ Agonist GFT505 Improves Hepatic and Peripheral Insulin Sensitivity in Abdominally Obese Subjects , 2013, Diabetes Care.

[13]  M. Huff,et al.  Peroxisome proliferator-activated receptor &dgr;: a multifaceted metabolic player , 2013, Current opinion in lipidology.

[14]  K. Cusi,et al.  The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association , 2012, The American Journal of Gastroenterology.

[15]  P. O’Connor,et al.  Fenofibrate-associated changes in renal function and relationship to clinical outcomes among individuals with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) experience , 2012, Diabetologia.

[16]  A. Keech,et al.  Benefits and Safety of Long-Term Fenofibrate Therapy in People With Type 2 Diabetes and Renal Impairment , 2012, Diabetes Care.

[17]  M. Ekstedt,et al.  Low clinical relevance of the nonalcoholic fatty liver disease activity score (NAS) in predicting fibrosis progression , 2012, Scandinavian journal of gastroenterology.

[18]  J. Heimbach,et al.  Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. , 2011, Gastroenterology.

[19]  E. Bruckert,et al.  Effects of the New Dual PPARα/δ Agonist GFT505 on Lipid and Glucose Homeostasis in Abdominally Obese Patients With Combined Dyslipidemia or Impaired Glucose Metabolism , 2011, Diabetes Care.

[20]  A. Baranova,et al.  Systematic review: the epidemiology and natural history of non‐alcoholic fatty liver disease and non‐alcoholic steatohepatitis in adults , 2011, Alimentary pharmacology & therapeutics.

[21]  N. Chalasani,et al.  Endpoints and clinical trial design for nonalcoholic steatohepatitis , 2011, Hepatology.

[22]  H. Makhlouf,et al.  Pathologic criteria for nonalcoholic steatohepatitis: Interprotocol agreement and ability to predict liver‐related mortality , 2011, Hepatology.

[23]  V. Gebski,et al.  Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study , 2011, Diabetologia.

[24]  B. Neuschwander‐Tetri,et al.  Therapeutic trials in nonalcoholic steatohepatitis: Insulin sensitizers and related methodological issues , 2010, Hepatology.

[25]  G. Alexander,et al.  Enhanced liver fibrosis test can predict clinical outcomes in patients with chronic liver disease , 2010, Gut.

[26]  H. Bonkovsky.  Prognostic Value of Ishak Fibrosis Stage: Findings from the HALT-C Trial , 2010 .

[27]  D. Houlihan,et al.  Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. , 2010, The New England journal of medicine.

[28]  G. Aithal,et al.  Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. , 2008, Gastroenterology.

[29]  Vidya Subramanian,et al.  Alternative M2 activation of Kupffer cells by PPARdelta ameliorates obesity-induced insulin resistance. , 2008, Cell metabolism.

[30]  T. Willson,et al.  Activation of Peroxisome Proliferator–Activated Receptor (PPAR)δ Promotes Reversal of Multiple Metabolic Abnormalities, Reduces Oxidative Stress, and Increases Fatty Acid Oxidation in Moderately Obese Men , 2008, Diabetes.

[31]  J. Hardies,et al.  A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. , 2006, The New England journal of medicine.

[32]  M. Holmqvist,et al.  Long‐term follow‐up of patients with NAFLD and elevated liver enzymes , 2006, Hepatology.

[33]  O. Yokosuka,et al.  Favorable prognosis of chronic hepatitis C after interferon therapy by long‐term cohort study , 2003, Hepatology.

[34]  Y Hochberg,et al.  Multiple test procedures for dose finding. , 1996, Biometrics.